Highlights

• The Body's HIV Experts Discuss IAS 2003

July 14, 2003

• HIV Drug Resistance
  
  • Use and Clinical Impacts of Drug Resistance Testing in HIV Infection (Forum 6)
    Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.
  • The Inhibitory Quotient of Tipranavir/Ritonavir in Triple Class Experienced HIV-Positive Patients; Results From BI 1182.52 (Forum 9)
    Coverage by Gerald Pierone, Jr., M.D.

• Immunopathogenesis and Immune Restoration
  
  • Thymic Volume Is Independently Associated With the Magnitude of CD4+ T-Cell Recovery After Short and Long Term on HAART (Oral 16)
    Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

• Antiretroviral Therapy
  
  • Emtricitabine, Didanosine and Efavirenz Once-Daily Versus Continued PI-Based HAART in HIV-Infected Adults With Undetectable Plasma HIV-RNA: 48-Week Results of a Prospective Randomized Multicenter Trial (ALIZE-ANRS 99) (Oral 37)
    Coverage by Calvin J. Cohen, M.D., M.S.
  • A Randomized, Double-Blind, Multicenter Comparison of Emtricitabine QD to Stavudine BID in Treatment-Naive HIV-Infected Patients (Oral 38)
    Coverage by Paul E. Sax, M.D.
  • ACTG 5095: A Comparative Study of Three Protease Inhibitor-Sparing Antiretroviral Regimens for the Initial Treatment of HIV Infection (Oral 41)
    Coverage by Brian A. Boyle, M.D., J.D.
  • Induction of Antiretroviral-Naive HIV-Infected Subjects With Trizivir and Sustiva for 48 Weeks (ESS40013) (Oral 42)
    Coverage by Andrew T. Pavia, M.D.
  • Early Virologic Failure in a Pilot Study Evaluating the Efficacy of Abacavir, Lamivudine and Tenofovir in the Treatment-Naive HIV-Infected Patients (Oral 43)
    Coverage by Timothy Wilkin, M.D., M.P.H.
  • Early Virologic Failure in a Pilot Study Evaluating the Efficacy of Abacavir, Lamivudine and Tenofovir in the Treatment-Naive HIV-Infected Patients (Oral 43)
    Coverage by Benjamin Young, M.D., Ph.D.

• Complications of Antiretroviral Therapy
  
  • A Randomized, Double-Blind, Placebo-Controlled Study of Rosiglitazone for Patients With HIV Lipodystrophy (Oral 50)
    Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.
  • Baseline Lactate Levels and CT Scan Values Predict the Regression of Lipoatrophy in CT Scan 48 Weeks After a Switch From Stavudine to Abacavir or Zidovudine (Oral 51)
    Coverage by Paul E. Sax, M.D.
  • Risks of Cardiovascular Disease Associated With Highly Active Antiretroviral Therapy Among Persons Treated for HIV/AIDS (Oral 52)
    Coverage by Gerald Pierone, Jr., M.D.
  • ACTG 5097s: Impact of Efavirenz on Neuropsychological Performance, Mood and Sleep Behavior in HIV-Positive Individuals (Oral 54)
    Coverage by Brian A. Boyle, M.D., J.D.
  • Incidence and Risk Factors for Severe Adverse Events in a Prospective Cohort of HIV-Infected Adults Started on a Protease Inhibitor-Containing Therapy (Oral 56)
    Coverage by Judith A. Aberg, M.D.
  • Gender and Race Subgroup Analyses in a Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Trizivir, Combivir/Nelfinavir, or Stavudine/Lamivudine/Nelfinavir (Oral 57)
    Coverage by Judith A. Aberg, M.D.

• Epidemiology, Morbidity and Mortality
  
  • Hormonal Contraception and Risk of HIV-1 Acquisition: Results of a 10-Year Prospective Study (Oral 83)
    Coverage by Timothy Wilkin, M.D., M.P.H.

• Therapeutic Vaccines
  
  • Is There a Prospect for Therapeutic Vaccination? (Controversy 98, 99)
    Coverage by Timothy Wilkin, M.D., M.P.H.

• Antiretroviral Treatment and Cardiovascular Risk
  
  • Should We Modify Antiretroviral Treatment Based on Cardiovascular Risk? (Controversy 100, 101)
    Coverage by Gerald Pierone, Jr., M.D.

• Clinical Trials of New Drugs/Pro-Drugs
  
  • 48-Week Results of an Atazanavir-Based QD Regimen in Patients Switching From BID PI-Based HAART (Poster 543)
    Coverage by Andrew T. Pavia, M.D.

• Phase III/IV Trials
  
  • Efficacy of Emtricitabine in HIV-Infected Patients With High Pre-Treatment Viral Load (Poster 546)
    Coverage by Andrew T. Pavia, M.D.
  • Once-Daily Emtricitabine Compared to Twice-Daily Abacavir Within a HAART Regimen in Antiretroviral Drug-Naive HIV-1-Infected Patients (ODECTA) (Poster 547)
    Coverage by Paul E. Sax, M.D.
  • Systematic Review of Nevirapine- Versus Efavirenz-Containing Three-Drug Regimens for Initial Treatment of HIV Infection (Poster 552)
    Coverage by Andrew T. Pavia, M.D.
  • Characterization of Virologic Failure Through 96 Weeks Among Treatment-Naive Patients Taking Tenofovir DF or Stavudine in Combination With Lamivudine and Efavirenz (Poster 553)
    Coverage by Calvin J. Cohen, M.D., M.S.
  • An Observational Cohort Comparison of Zidovudine-Lamivudine-Efavirenz to Zidovudine-Lamivudine-Abacavir in Antiretroviral-Naive Individuals (Poster 554)
    Coverage by Brian A. Boyle, M.D., J.D.
  • Long-Term Safety and Efficacy of Two Antiretroviral Therapies Combivir + Abacavir Versus Combivir + Nelfinavir-Ecureuil 2-(CNAF3021) (Poster 556)
    Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

• Treatment of Primary HIV Infection
  
  • Lack of Resistance to Boosted 908 Observed Through 48 Weeks of Therapy in Naive Subjects (Poster 558)
    Coverage by Andrew T. Pavia, M.D.

• Initiation of Therapy
  
  • Similar 96-Week Efficacy Profile Regardless of Baseline Characteristic Variable for Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients (Poster 559)
    Coverage by Calvin J. Cohen, M.D., M.S.
  • Favorable Metabolic Profile for Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients: 96-Week Interim Results (Poster 562)
    Coverage by Paul E. Sax, M.D.
  • Predictors of CD4 at HAART Initiation (Poster 567)
    Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

• Treatment Simplification
  
  • Pilot Study: Ritonavir Boosted Indinavir Treatment as a Simplified Maintenance "Mono"-Therapy for HIV Infection (Poster 589)
    Coverage by Gerald Pierone, Jr., M.D.
  • Long-Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV Patients With Undetectable Viral Load (Poster 590)
    Coverage by Andrew T. Pavia, M.D.
  • Impact of Two Simplified Therapies With Three Nucs and Two Nucs Plus NNRTI on Quality of Life and Adherence in HIV-1-Infected Patients With Undetectable Viral Load (Poster 592)
    Coverage by Timothy Wilkin, M.D., M.P.H.
  • Efficacy of Trizivir and Tenofovir as HAART for HIV-Infected Patients With Current or Underlying Reverse Transcriptase Resistance (Poster 593)
    Coverage by Gerald Pierone, Jr., M.D.

• Immunologic and Virologic Limitations of HAART
  
  • Comparison of Triple (AZT/3TC/EFV) Versus Quad (AZT/3TC/ABC/EFV) in ARV-Naive Patients With High Viral Load (>100 000 c/mL) Using a DAVG Analysis and a <5 c/mL VL Assay (Quad Study) (Poster 615)
    Coverage by Paul E. Sax, M.D.

• Lipids and Metabolic Complications
  
  • Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Trizivir, Combivir/Nelfinavir, or Stavudine/Lamivudine/Nelfinavir (Poster 709)
    Coverage by Timothy Wilkin, M.D., M.P.H.

• Lipoatrophy
  
  • Differential Effect of HIV Protease Inhibitors on Adipogenesis: Intracellular Ritonavir Is Not Sufficient to Inhibit Differentiation (Poster 724)
    Coverage by Robert J. Frascino, M.D.
  • A Prospective Cohort Study on the Risk of Lipodystrophy in HIV-1-Infected Patients Who Have Never Received Protease Inhibitors (Poster 725)
    Coverage by Robert J. Frascino, M.D.
  • Morphological Changes After 48 Months on Sparing-NRTI Antiretroviral Therapy in Patients With Facial Lipoatrophy (Poster 726)
    Coverage by Robert J. Frascino, M.D.
  • Effect of Tenofovir, Stavudine, and Zidovudine on Adipocyte Function (Poster 727)
    Coverage by Robert J. Frascino, M.D.
  • 3D Computed Tomography to Evaluate Lipoatrophy in HIV Infected Patients (Poster 728)
    Coverage by Robert J. Frascino, M.D.

• Mitochondrial Toxicities
  
  • Overview of the Incidence of Symptomatic Hyperlactatemia With Emtricitabine (Poster 737)
    Coverage by Gerald Pierone, Jr., M.D.

• Genotyping and Phenotyping
  
  • Tipranavir/Ritonavir Demonstrates a Robust Resistance Profile in Multiple Protease Inhibitor-Experienced Patients: Correlation of Baseline-Genotype and Antiviral Activity in BI 1182.52 (Poster 812)
    Coverage by Gerald Pierone, Jr., M.D.

• Resistance Testing in Clinical Practice
  
  • Genotypic Resistance Profiles in HIV-1 Reverse Transcriptase During Therapy With Trizivir (Zidovudine + Lamivudine + Abacavir) in Antiretroviral Treatment-Naive HIV-1-Infected Patients (Poster 828)
    Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

• Drug Interactions
  
  • Standard Doses of Efavirenz, Zidovudine, Tenofovir, and Didanosine May Be Given With Tipranavir/Ritonavir (Poster 865)
    Coverage by Gerald Pierone, Jr., M.D.

• Morbidity/Mortality in the Era of HAART
  
  • Anemia Prevalence Among HIV Patients: Antiretroviral Therapy and Other Risk Factors (Poster 1151)
    Coverage by Robert J. Frascino, M.D.
  • Association of Treatments for Anemia and Survival Among Persons With HIV Infection and Anemia (Poster 1154)
    Coverage by Robert J. Frascino, M.D.

July 15, 2003

• Salvage Therapy
  
  • Efficacy and Safety of Atazanavir With Ritonavir or Saquinavir Versus Lopinavir/Ritonavir in Combination With Tenofovir and One NRTI in Patients Who Have Experienced Virologic Failure to Multiple HAART Regimens: 16-Week Results From BMS AI424-045 (Forum 118)
    Coverage by Calvin J. Cohen, M.D., M.S.
  • Failure of Structured Treatment Interruption to Confer Benefit in the Setting of Treatment Failure: CPCRA 064 Results by Baseline CD4 Count and Phenotypic Sensitivity Score Subgroups (Forum 119)
    Coverage by Gerald Pierone, Jr., M.D.

• Resistance and Pharmacology
  
  • Efficacy of Ritonavir/Amprenavir-Containing Regimen in HIV-1 Protease Inhibitor-Experienced Patients and Predictivity of the Delta Viral Load Values Up to Week 24 Using Genotypic Inhibitory Quotient (Oral 165)
    Coverage by Judith A. Aberg, M.D.

• Treatment Interruptions: Pros and Cons
  
  • There Is More Risk Than Value in Treatment Interruptions (Controversy 194, 195)
    Coverage by Gerald Pierone, Jr., M.D.

• FRAM Results
  
  • Insights From the Preliminary Results of the Fat Redistribution and Metabolic Change in HIV Infection Study (FRAM) (Institutional Symposium -- NIH)
    Coverage by Timothy Wilkin, M.D., M.P.H.

July 16, 2003

• Co-Infection With Hepatitis
  
  • Anti-HBV Activity of Emtricitabine in Patients Co-Infected With HIV and Hepatitis B Virus (Forum 215)
    Coverage by Gerald Pierone, Jr., M.D.

• Late Breakers
  
  • Enfuvirtide TORO Studies: 48-Week Results Confirm 24-Week Findings (Oral LB2)
    Coverage by Andrew T. Pavia, M.D.
  • Failures of One Week On, One Week Off Antiretroviral Therapies in a Randomized Trial (Oral LB4)
    Coverage by Gerald Pierone, Jr., M.D.
  • Atazanavir and Efavirenz Have Similar Effects on Body Fat Distribution in Antiretroviral-Naive Patients When Combined With Fixed-Dose Zidovudine and Lamivudine: 48-Week Results From the Metabolic Substudy of BMS AI424-034 (Oral LB13)
    Coverage by Calvin J. Cohen, M.D., M.S.
  • Antiretroviral Activity, Safety and Pharmacokinetics of TMC114, a Next-Generation HIV-1 Protease Inhibitor, in Multiple PI-Experienced Patients (Oral LB16)
    Coverage by Andrew T. Pavia, M.D.